scholarly journals Respiratory Syncytial Virus Infections among Children with Congenital Heart Disease

2019 ◽  
Author(s):  
Maja Daurach ◽  
Ina Michel-Behnke
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Respiratory Syncytial Virus ◽  
Congenital Heart ◽  
Virus Infections ◽  
Respiratory Syncytial Virus Infections ◽  
Syncytial Virus

scholarly journals 40 Respiratory syncytial virus-related outcomes from an abbreviated palivizumab dose regimen in children with congenital heart disease

2019 ◽  
Vol 24 (Supplement_2) ◽  
pp. e16-e17
Author(s):  
Pascal Lavoie ◽  
Jennifer Claydon ◽  
Constantin Popescu ◽  
Lana Shaibah ◽  
Cheryl Christopherson ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Respiratory Syncytial Virus ◽  
Dose Regimen ◽  
Congenital Heart ◽  
Syncytial Virus

Impact of respiratory syncytial virus infection on surgery for congenital heart disease: Postoperative course and outcome

1999 ◽  
Vol 27 (9) ◽  
pp. 1974-1981 ◽  
Author(s):  
Apichai Khongphatthanayothin ◽  
Pierre C. Wong ◽  
Yousef Samara ◽  
Christopher J. L. Newth ◽  
Winfield J. Wells ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Respiratory Syncytial Virus ◽  
Virus Infection ◽  
Respiratory Syncytial Virus Infection ◽  
Congenital Heart ◽  
Postoperative Course ◽  
Syncytial Virus

RESPIRATORY SYNCYTIAL VIRUS MORBIDITY AND MORTALITY ESTIMATES IN CONGENITAL HEART DISEASE PATIENTS: A RECENT EXPERIENCE

PEDIATRICS ◽  
1993 ◽  
Vol 92 (4) ◽  
pp. 642-642
Author(s):  
J. F. L.
Keyword(s):  
Congenital Heart Disease ◽  
Intensive Care ◽  
Heart Disease ◽  
Respiratory Syncytial Virus ◽  
Congenital Heart ◽  
Pediatric Intensive Care ◽  
Mortality Rates ◽  
Recent Experience ◽  
Duration Of Hospitalization ◽  
Syncytial Virus

In conclusion, present respiratory syncytial virus mortality rates in pediatric patients with congenital heart disease are much less than those described nearly a decade ago. Patients with pulmonary hypertension have increased mortality rates as measured by duration of hospitalization, need for and duration of intensive care, and requirement and duration of mechanical ventilation. However, greatly increased mortality risk is not currently seen in congenital heart disease patients with pulmonary arterial hypertension compared with those congenital heart disease patients without this diagnosis. The substantially reduced mortality rate differences observed between the present congenital heart disease patients and patients of a decade ago are probably due to advances in pediatric intensive care medicine and surgical management of heart disease. It is unlikely that the availability of ribavirin alone has been responsible for the marked reduction in respiratory syncytial virus congenital heart disease mortality rates. Appropriately designed studies addressing efficacy, cost-effectiveness, and short- and long-term safety of ribavirin use in patients with congenital heart disease are still needed.

Sign in / Sign up

Export Citation Format

Share Document